A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 2
Part of paid clinical trials in Little Rock, Arkansas.
- Sponsor
- Alkermes, Inc.
- Study ID
- NCT06555783
- Phase
- PHASE2
- Status
- Completed
Conditions
- Narcolepsy Type 2
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 70 Years
- Healthy Volunteers
- Not accepted
Interventions
- ALKS 2680 — DRUGOral tablet containing ALKS 2680
- Placebo — DRUGOral tablet containing placebo for once daily administration
Study Details
The purpose of this study is to measure the safety and decrease in sleepiness in subjects with narcolepsy type 2 (NT2) when taking ALKS 2680 tablets compared to placebo tablets.
Key Dates
- Start date
- Jul 26, 2024
- Status verified
- Feb 2026
- Primary completion
- Nov 11, 2025
- Completion
- Nov 21, 2025
Study Design
- Enrollment
- 93 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: ALKS 2680, 10 mgOral tablet containing 10mg of ALKS 2680 for once daily administration
- Experimental: ALKS 2680, 14 mgOral tablet containing 14mg of ALKS 2680 for once daily administration
- Experimental: ALKS 2680, 18 mgOral tablet containing 18mg of ALKS 2680 for once daily administration
- Placebo Comparator: PlaceboOral tablet containing matching placebo for once daily administration
Primary Outcome Measure
Change in Mean Sleep Latency (MSL) on the Maintenance Wakefulness Test (MWT) [ Time Frame: Baseline to Week 8 ]
Locations (33)
Find similar trials in Little Rock, AR
Related Studies
- A Study of ORX750 in Participants With Narcolepsy and Idiopathic HypersomniaPHASE2 · Recruiting · Centessa Pharmaceuticals (UK) Limited · Auburn, Alabama
- A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic HypersomniaPHASE2/PHASE3 · Recruiting · Alkermes, Inc. · Phoenix, Arizona
- A Study of TAK-360 in Adults With Narcolepsy Without Cataplexy (NT2)PHASE2 · Recruiting · Takeda · Auburn, Alabama
- A Long-term Extension Study of ORX750 in Participants With Narcolepsy and Idiopathic HypersomniaPHASE2 · Recruiting · Centessa Pharmaceuticals (UK) Limited · Auburn, Alabama